Reviva Pharm Holdings Initiated at Buy by EF Hutton
Express News | Reviva Pharmaceuticals Holdings, Inc. - Statistically Significant Vocal Biomarker Data Reinforce Efficacy of Brilaroxazine
Express News | Reviva Pharmaceuticals Holdings, Inc.: Additional Vocal Biomarker Data From Ongoing Open Label Extension Study Expected Q4 2024
Maxim Group Maintains Reviva Pharmaceuticals(RVPH.US) With Hold Rating
Maxim Group analyst Jason McCarthy maintains $Reviva Pharmaceuticals(RVPH.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 24.3% and a total average return of -22.
Maxim Group Reaffirms Their Hold Rating on Reviva Pharmaceuticals Holdings (RVPH)
Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Reviva to Host Virtual KOL Event to Discuss Vocal Biomarker Data From Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia on September 4, 2024
Reviva Pharm Holdings Price Target Maintained With a $17.00/Share by Benchmark
Benchmark Reiterates Speculative Buy on Reviva Pharmaceuticals, Maintains $17 Price Target
Reviva Pharmaceuticals Launches Multi-Million Share Offering
Eyenovia EYEN Offering; Reviva Pharmaceuticals RVPH Offering
Top Midday Decliners
Reviva Pharmaceuticals Stock Falls After It Prices $5M Offering
Reviva Pharmaceuticals Priced An Underwritten Offering Of 4.76M Shares (Or Pre-funded Warrants In Lieu Thereof) And Investor Warrants To Purchase Up To 4.76M Shares, Combined Price Of Each Share And Accompanying Warrant Is $1.05 And Each Pre-funded...
Express News | Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced at-the-Market Under Nasdaq Rules
Maxim Group Downgrades Reviva Pharmaceuticals(RVPH.US) to Hold Rating
Maxim Group analyst Jason McCarthy downgrades $Reviva Pharmaceuticals(RVPH.US)$ to a hold rating.According to TipRanks data, the analyst has a success rate of 24.4% and a total average return of -22.1
Express News | Reviva Pharmaceuticals Holdings, Inc. : Maxim Group Cuts to Hold From Buy
Reviva Pharmaceuticals GAAP EPS of -$0.26
10-Q: Q2 2024 Earnings Report
Reviva Pharmaceuticals 2Q-End Cash About $6.2M >RVPH